Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey


Sag S., Kaderli A. A., YILDIZ A., Gul B. C., ÖZDEMİR B., Baran I., ...More

TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, vol.45, no.5, pp.415-425, 2017 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 45 Issue: 5
  • Publication Date: 2017
  • Doi Number: 10.5543/tkda.2017.80026
  • Journal Name: TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.415-425
  • Keywords: Aquaretic treatment, congestive heart failure, hyponatremia, tolvaptan, REDUCED EJECTION FRACTION, VASOPRESSIN V-2-RECEPTOR ANTAGONIST, EVEREST TRIAL, PROGNOSTIC VALUE, DOUBLE-BLIND, INSIGHTS, REGISTRY, RATIONALE, BLOCKADE, OUTCOMES
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

Objective: The aim of the present study was to assess the efficacy and safety of tolvaptan for severe hyponatremia (SH) in hypervolemic heart failure (HF) patients within daily clinical practice.